A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review
We previously reported a case of giant cell carcinoma in the lung, in which the use of antiprogrammed death 1 (PD-1) immunotherapy resulted in substantial tumor reduction. In the present study, we describe an additional clinical course. A 69-year-old woman was diagnosed with giant cell carcinoma of...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/1763625 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568413195599872 |
|---|---|
| author | Tomoo Kakimoto Mamoru Sasaki Tatsuya Yamamoto Arifumi Iwamaru Kentaro Ogata Ko Lee Shingo Nakayama Naoto Minematsu |
| author_facet | Tomoo Kakimoto Mamoru Sasaki Tatsuya Yamamoto Arifumi Iwamaru Kentaro Ogata Ko Lee Shingo Nakayama Naoto Minematsu |
| author_sort | Tomoo Kakimoto |
| collection | DOAJ |
| description | We previously reported a case of giant cell carcinoma in the lung, in which the use of antiprogrammed death 1 (PD-1) immunotherapy resulted in substantial tumor reduction. In the present study, we describe an additional clinical course. A 69-year-old woman was diagnosed with giant cell carcinoma of the lung in clinical stage IVB (T2bN0M1c, BRA). The tumor expressed programmed death ligand 1 (PD-L1) in a high proportion. The patient received stereotactic radiotherapy for two sites of small brain metastases, followed by immunotherapy using anti-PD-1 antibodies (pembrolizumab). The treatment exerted a substantial tumor reduction through four cycles. However, treatment was withdrawn due to renal dysfunction. The primary lung tumor continued to regress for an additional four months without any further therapy, resulting in a clinical stage of T1aN0M0. Salvage thoracic surgery was then performed to remove the tumor residue in the lung. Microscopic examination of the sample revealed no residual cancer. The patient was free from recurrence at 16 months post surgery. We then comprehensively reviewed lung sarcomatoid carcinoma cases in the literature, in which anti-PD-1 antibodies were implemented. The current literature and our own findings suggest sarcomatoid carcinomas express high levels of tumoral PD-L1 and can be effectively treated with anti-PD-1 antibodies. |
| format | Article |
| id | doaj-art-1bd66fec8c4a410f96aeca1565fe6942 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-1bd66fec8c4a410f96aeca1565fe69422025-02-03T00:59:03ZengWileyCase Reports in Oncological Medicine2090-67062090-67142019-01-01201910.1155/2019/17636251763625A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature ReviewTomoo Kakimoto0Mamoru Sasaki1Tatsuya Yamamoto2Arifumi Iwamaru3Kentaro Ogata4Ko Lee5Shingo Nakayama6Naoto Minematsu7Department of Internal Medicine Hino Municipal Hospital, Hino-shi, Tokyo, JapanDepartment of Internal Medicine Hino Municipal Hospital, Hino-shi, Tokyo, JapanDepartment of Surgery, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tachikawa-shi, Tokyo, JapanDepartment of Surgery, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tachikawa-shi, Tokyo, JapanDepartment of Pathology, Federation of National Public Service Personnel Mutual Aid Associations, Tachikawa Hospital, Tachikawa-shi, Tokyo, JapanDepartment of Internal Medicine Hino Municipal Hospital, Hino-shi, Tokyo, JapanDepartment of Internal Medicine Hino Municipal Hospital, Hino-shi, Tokyo, JapanDepartment of Internal Medicine Hino Municipal Hospital, Hino-shi, Tokyo, JapanWe previously reported a case of giant cell carcinoma in the lung, in which the use of antiprogrammed death 1 (PD-1) immunotherapy resulted in substantial tumor reduction. In the present study, we describe an additional clinical course. A 69-year-old woman was diagnosed with giant cell carcinoma of the lung in clinical stage IVB (T2bN0M1c, BRA). The tumor expressed programmed death ligand 1 (PD-L1) in a high proportion. The patient received stereotactic radiotherapy for two sites of small brain metastases, followed by immunotherapy using anti-PD-1 antibodies (pembrolizumab). The treatment exerted a substantial tumor reduction through four cycles. However, treatment was withdrawn due to renal dysfunction. The primary lung tumor continued to regress for an additional four months without any further therapy, resulting in a clinical stage of T1aN0M0. Salvage thoracic surgery was then performed to remove the tumor residue in the lung. Microscopic examination of the sample revealed no residual cancer. The patient was free from recurrence at 16 months post surgery. We then comprehensively reviewed lung sarcomatoid carcinoma cases in the literature, in which anti-PD-1 antibodies were implemented. The current literature and our own findings suggest sarcomatoid carcinomas express high levels of tumoral PD-L1 and can be effectively treated with anti-PD-1 antibodies.http://dx.doi.org/10.1155/2019/1763625 |
| spellingShingle | Tomoo Kakimoto Mamoru Sasaki Tatsuya Yamamoto Arifumi Iwamaru Kentaro Ogata Ko Lee Shingo Nakayama Naoto Minematsu A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review Case Reports in Oncological Medicine |
| title | A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review |
| title_full | A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review |
| title_fullStr | A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review |
| title_full_unstemmed | A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review |
| title_short | A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review |
| title_sort | histologically complete response to immunotherapy using pembrolizumab in a patient with giant cell carcinoma of the lung an additional report and literature review |
| url | http://dx.doi.org/10.1155/2019/1763625 |
| work_keys_str_mv | AT tomookakimoto ahistologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT mamorusasaki ahistologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT tatsuyayamamoto ahistologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT arifumiiwamaru ahistologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT kentaroogata ahistologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT kolee ahistologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT shingonakayama ahistologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT naotominematsu ahistologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT tomookakimoto histologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT mamorusasaki histologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT tatsuyayamamoto histologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT arifumiiwamaru histologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT kentaroogata histologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT kolee histologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT shingonakayama histologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview AT naotominematsu histologicallycompleteresponsetoimmunotherapyusingpembrolizumabinapatientwithgiantcellcarcinomaofthelunganadditionalreportandliteraturereview |